NFL Biosciences: new patent application filed - 02/11/2022 at 11:01

NFL Biosciences: new patent application filed – 02/11/2022 at 11:01

( – The stock of the biopharmaceutical company NFL Biosciences rose sharply on the Paris Stock Exchange on Wednesday following the filing of a new patent application, supposed to precede the launch of dedicated clinical studies.

In a press release released in the morning, NFL specifies that its patent application aims to protect the administration of NFL-101, its most advanced product, in combination with other smoking cessation treatments and in particular nicotine substitutes.

The application was initially filed in the United States and will be extended internationally, underlines the Montpellier company.

Nicotine substitutes – which include patches, tablets, chewing gum and sprays – represent around 80% of the market despite a six-month effectiveness deemed ‘modest’, recalls the company.

NFL Biosciences believes that its standardized, nicotine-free tobacco leaf extract could have a ‘major’ competitive advantage when prescribed either alone or in combination with other treatments to increase their effectiveness.

Listed on Euronext Growth Paris, the NFL title is currently jumping 25% after having taken nearly 35% in the middle of the morning.


Leave a Comment

Your email address will not be published. Required fields are marked *